Trial Profile

A multi-centre, randomised, double blind, placebo controlled study to determine the optimal effective and safe dose of Pollinex Quattro Grass 1.0 mL (Allergy Therapeutics, (UK) Ltd.) for the treatment of patients with seasonal allergic rhinoconjunctivitis due to grass pollen

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Feb 2019 Results assessing a strong dose-response Using a Conjunctival Provocation Test, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
25 Feb 2019 Results assessing Strong Dose-response On Immunoglobulin Makers, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
25 Jun 2018 According to an Allergy Therapeutics media release, company announces the publication of positive data in the journal Immunotherapy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com